Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
35.11
+0.50 (1.44%)
At close: Oct 8, 2025, 4:00 PM EDT
35.10
-0.01 (-0.03%)
After-hours: Oct 8, 2025, 4:00 PM EDT
Veracyte Employees
Veracyte had 824 employees as of December 31, 2024. The number of employees increased by 9 or 1.10% compared to the previous year.
Employees
824
Change (1Y)
9
Growth (1Y)
1.10%
Revenue / Employee
$581,467
Profits / Employee
$31,960
Market Cap
2.76B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 824 | 9 | 1.10% |
| Dec 31, 2023 | 815 | 28 | 3.56% |
| Dec 31, 2022 | 787 | 26 | 3.42% |
| Dec 31, 2021 | 761 | 441 | 137.81% |
| Dec 31, 2020 | 320 | -34 | -9.60% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VCYT News
- 10 days ago - Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer - Business Wire
- 14 days ago - Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 - Business Wire
- 4 weeks ago - Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting - Business Wire
- 5 weeks ago - Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 6 weeks ago - Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer - Business Wire
- 6 weeks ago - Veracyte: Q2 Earnings Brings My Position Out Of Mothballs - Seeking Alpha
- 6 weeks ago - Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test - Business Wire